CAS 84449-90-1
:Raloxifen
- [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
- Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-
- Raloxifene
- Keoxifene
- LY 139481
Raloxifene Hydrochloride
CAS:Formel:C28H27NO4S·HClReinheit:>98.0%(T)(HPLC)Farbe und Form:Light yellow to Yellow to Green powder to crystalMolekulargewicht:510.05Raloxifene
CAS:Raloxifene (LY139481) is an estrogen receptor modulator exhibiting estrogen agonist and antagonist activity at different sites, with antiviral activity.Formel:C28H27NO4SReinheit:99.39%Farbe und Form:Light-Yellow SolidMolekulargewicht:473.58Ref: TM-T20419
2mg39,00€5mg58,00€10mg92,00€25mg177,00€50mg264,00€100mg391,00€200mg567,00€1mL*10mM (DMSO)62,00€Raloxifene
CAS:Kontrolliertes ProduktApplications Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
References Jone, C.D., et al.: J. Med. Chem., 27, 1057 (1984); Buelke-Sam, J., et al.: Reprod. Toxicol., 12, 217 (1998)Formel:C28H27NO4SFarbe und Form:Off White SolidMolekulargewicht:473.582-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol
CAS:Formel:C28H27NO4SReinheit:98%Farbe und Form:SolidMolekulargewicht:473.5833Raloxifene
CAS:Kontrolliertes ProduktRaloxifene is a non-steroidal drug that binds to estrogen receptors, which may be useful in the treatment of postmenopausal osteoporosis. Raloxifene has been shown to increase bone mineral density and reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. Raloxifene also has been found to decrease breast cancer risk by about 50% in postmenopausal women. The drug binds to estrogen receptors in breast tissue, preventing the stimulation of these cells by estrogen and decreasing their growth rate. Raloxifene also inhibits the production of lactogenic hormones such as prolactin and progesterone that are involved in breast cancer development. Raloxifene hydrochloride is used at doses between 60 mg and 120 mg per day for a duration of 5 years.
Raloxifene hydrochloride is not active against estrogen receptor positive tumors and should not be used for treatment of breast cancer.Formel:C28H27NO4SReinheit:Min. 95%Farbe und Form:PowderMolekulargewicht:473.58 g/mol





